Baxter International Inc. (BAX) continues to hold a Wall Street consensus hold rating, with analysts citing stable financial performance and moderate growth amid cautious macroeconomic conditions. The stock reflects a balanced outlook across major investment firms.
- Baxter International (BAX) holds a Wall Street consensus hold rating as of December 9, 2025.
- Average analyst price target is $117.50, representing a 2.3% upside from current levels.
- 2024 full-year revenue: $9.4 billion, up 3.1% YoY.
- Adjusted EPS for 2024: $5.22, up 4.7% YoY.
- FX headwinds reduced reported revenue growth by 1.2 percentage points.
- Analysts cite balanced outlook due to steady performance and macroeconomic caution.
Baxter International Inc. (BAX) remains under a consensus hold recommendation from Wall Street analysts as of the latest review period, signaling neither strong optimism nor significant concern among institutional investors. The consensus reflects a range of price targets around $110 to $125 per share, with an average target of $117.50, indicating a modest 2.3% upside from current levels as of December 9, 2025. Analysts highlight Baxter's consistent revenue performance, with full-year 2024 revenue reaching $9.4 billion, growing 3.1% year-over-year, driven by steady demand in its renal and specialty pharmaceuticals divisions. The company reported adjusted earnings per share of $5.22 for the fiscal year, up 4.7% compared to the prior year, which supports the neutral stance despite limited near-term catalysts. The hold rating comes amid broader market caution in the healthcare sector, where regulatory scrutiny and pricing pressures in key markets have tempered growth expectations. Baxter's reliance on international markets, particularly in Europe and Asia, adds complexity, with foreign exchange headwinds reducing reported revenue growth by approximately 1.2 percentage points in 2024. Investors and fund managers tracking large-cap healthcare stocks are monitoring Baxter's progress on pipeline innovation, including its advanced dialysis systems and biosimilars development, which could influence future ratings. The current hold consensus suggests that analysts believe the stock is fairly valued, with risks and rewards in balance.